Raymond James Downgrades Verastem (VSTM) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
JMP Securities Downgrades Verastem (VSTM) to Market Perform
September 29, 2015 8:26 AM EDTJMP Securities downgraded Verastem (NASDAQ: VSTM) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $1.85 yesterday.
... MoreJefferies Downgrades Verastem (VSTM) to Hold
September 28, 2015 4:43 PM EDTJefferies downgraded Verastem (NASDAQ: VSTM) from Buy to Hold with a price target of $2.00 (from $18.00).
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $5.67 yesterday.
... MoreUBS Downgrades Verastem (VSTM) to Neutral
September 28, 2015 1:27 PM EDTUBS downgraded Verastem (NASDAQ: VSTM) from Buy to Neutral with a price target of $2.00.
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $5.67 yesterday.
... MoreMizuho Securities Downgrades Verastem (VSTM) to Neutral
September 28, 2015 1:25 PM EDTMizuho Securities downgraded Verastem (NASDAQ: VSTM) from Outperform to Neutral with a price target of $2.00 (from $21.00).
Analyst Eric Criscuolo commented, "We are downgrading VSTM from Buy to Neutral and lowering our PT from $21 to $2 following the failure of the COMMAND trial of... More
Roth Capital Downgrades Verastem (VSTM) to Neutral
September 28, 2015 9:37 AM EDTRoth Capital downgraded Verastem (NASDAQ: VSTM) from Buy to Neutral with a price target of $2.00 (from $23.00).
Analyst Joseph Pantginis commented, "There has been a major disappointment this morning as the pivotal COMMAND study using VS-6063 in mesothelioma was halted for futility following the... More
Verastem (VSTM) Ceases VS-6063 Phase 2 Enrollment in Mesothelioma Following DSMB Recommendation
September 28, 2015 7:01 AM EDTVerastem (NASDAQ: VSTM) announced that the Company has stopped enrollment in the Phase 2 registration-directed, double-blind, placebo-controlled study (COMMAND) of VS-6063 for patients with mesothelioma. The decision to stop enrollment for futility followed a Data Safety Monitoring Board (DSMB) review of a pre-planned interim analysis. The results of the analysis demonstrated that VS-6063 had a generally well... More
